Nvidia-backed AI firm Iambic unveils drug discovery ‘breakthrough’

Press

This is some text inside of a div block.

October 29, 2024

Media Contacts

Related announcements

Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins

Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins

Iambic to Participate in June Investor Conferences

Iambic to Participate in June Investor Conferences

Iambic Announces Enchant v2, its Next Generation AI Model for Predicting the Clinical Viability of Drug Discovery Programs

Iambic Announces Enchant v2, its Next Generation AI Model for Predicting the Clinical Viability of Drug Discovery Programs